McKesson Corp (MCK)

McKesson Corp (MCK-N) stands out as the largest pharmaceutical distributor in the U.S., demonstrating remarkable stability and predictability despite recent market rotations impacting healthcare stocks. Analysts highlight a solid earnings growth forecast of 12-13%, alongside a consistent dividend growth rate of 14% over the past five years. The company's strong market position, accounting for a significant share of the industry, coupled with favorable demographic trends, positions it well for long-term success. Upcoming strategic plans, such as the spinoff of its medical/surgical unit, are anticipated to unlock hidden value, and analysts maintain a bullish sentiment with price targets ranging from around $932 to over $1,002. Overall, McKesson remains a compelling choice for investors seeking exposure in a defensive sector that meets essential healthcare needs.